Abstract: Pancreatic adenocarcinoma (PAC) is a highly lethal disease for human being. Surgery in the past 100 years, novel drug combination and neoadjuvant therapy haven′t changed the prognosis of PAC fundamentally. Traditionally, authors only focused on the treatment in term of morphological changes, while it′s tumor biology that will ultimately determine the long-term survival of PAC patients. Surgeons should continuously pursue the radical resection of pancreatic cancer, however,with the guidance of tumor biology. Omics′ researches, artificial intelligence and next generation platform of translational study will improve our understanding and treatment for PAC.